Barclays lowered the firm’s price target on HCA Healthcare (HCA) to $392 from $396 and keeps an Overweight rating on the shares. While 2024 was a “particularly great” year for hospitals, 2025 is also attractive and there is earnings upside for both HCA and Tenet with reasonable organic growth assumptions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $400 from $395 at Wells Fargo
- HCA Healthcare price target raised to $400 from $390 at Oppenheimer
- HCA Healthcare price target lowered to $440 from $450 at TD Cowen
- HCA Healthcare price target lowered to $406 from $427 at Morgan Stanley
- HCA Healthcare price target lowered to $420 from $475 at KeyBanc